Immunotherapy
Hematopoietic stem cell researcher to receive lecture award
The International Society for Stem Cell Research will honor Margaret A. “Peggy” Goodell, PhD, with the Tobias Lecture Award.
CAR T-cell therapy for children: Meeting patient and family needs
Chimeric antigen receptor T-cell therapy is a promising immunotherapy for children with refractory or relapsed acute lymphoblastic leukemia who otherwise have limited treatment options.
Talimogene laherparepvec-pembrolizumab combination appears safe, effective in advanced sarcoma
Talimogene laherparepvec in combination with pembrolizumab demonstrated antitumor activity among patients with advanced sarcoma across a range of histologic subtypes, according to results of a single-arm phase 2 study published in JAMA Oncology.
FDA clears IND application for natural killer cell therapy for glioblastoma multiforme
The FDA cleared an investigational new drug application for CYNK-001, a natural killer cell therapy, for the treatment of glioblastoma multiforme.
Astellas partners with Adaptimmune to develop off-the-shelf CAR-T and T-cell therapies
Astellas Pharma announced a research and commercialization deal with Adaptimmune for the codevelopment of new stem cell-derived allogeneic chimeric antigen receptor and other T-cell therapies for the treatment of cancer.
Cytovia partners with UCSF, New York Stem Cell Foundation to develop novel CAR-NK cell therapies
Cytovia Therapeutics announced research partnerships with both The New York Stem Cell Foundation Research Institute and University of California, San Francisco, for the development of induced pluripotent stem cell-derived chimeric antigen receptor-natural killer cell therapies for cancer.
High BMI linked to longer survival with immunotherapy for non-small cell lung cancer
High baseline BMI appeared to be independently associated with improved survival among patients with non-small cell lung cancer who received atezolizumab, according to results of a retrospective study published in JAMA Oncology.
Addition of pembrolizumab to chemotherapy fails to extend OS in small cell lung cancer
The addition of pembrolizumab to first-line chemotherapy extended PFS but failed to significantly extend OS among patients with extensive-stage small cell lung cancer, according to topline data released by the agent’s manufacturer.
‘Immunotransplant’ shows potential for non-Hodgkin lymphoma
A combination of immunotherapy and stem cell transplantation could benefit patients with treatment-resistant non-Hodgkin lymphoma, according to preclinical data published in Cancer Discovery.
Avelumab maintenance extends OS in advanced urothelial carcinoma
The addition of maintenance avelumab to best supportive care extended OS for patients with previously untreated locally advanced or metastatic urothelial carcinoma, according to study results released by the agent’s manufacturer.